Vertex Pharmaceuticals (VRTX) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 20262026-27 catalysts
Povetacicept’s IgAN PDUFA date is Nov. 30, 2026; phase II proof-of-concept data in DM1 are expected by year-end 2026.
AMPLITUDE phase III interim analysis of inaxaplin in APOL1-mediated kidney disease is expected in Q1 2027; positive results could support an accelerated-approval filing.
Povetacicept phase II proof-of-concept data in myasthenia gravis are expected in H1 2027; the study is fully enrolled.
Suzetrigine phase III diabetic peripheral neuropathy data are expected mid-2027; both 12-week studies are set to complete enrollment by end-2026.
Povetacicept clinical profile and opportunity
Interim IgAN results: 52% proteinuria reduction at week 36, >80% hematuria resolution and 42% of patients reaching KDIGO guidelines.
Proposed convenience profile: at-home, once-every-four-weeks auto-injector with a 0.46 mL dose and lower viscosity than peers.
Serious infections were 0.5% in both placebo and drug arms; management expects a class-consistent label without IgG monitoring and cited an on-track Nov. 30 PDUFA.
Two-year eGFR endpoint is important for Europe and Asian markets; estimated IgAN population is 1.5-1.6 million globally, versus 160,000 diagnosed in the U.S. and a similar population in Europe.
Commercial partners include Ono Pharma in Japan and surrounding countries and Zai Lab in China and surrounding countries; povetacicept is being developed for primary membranous nephropathy as well.
Inaxaplin and kidney pipeline
APOL1-related kidney decline was cited at 6-7 mL/min/year for patients with two variants, versus ~4 mL/min/year without them; initial phase II showed a 47.6% proteinuria reduction at week 13.
AMPLITUDE tests inaxaplin in patients with proteinuria of 0.7 g/g or higher; FDA discussions focus on eGFR slope, which must be met for accelerated approval.
AMPLIFIED showed a 44% proteinuria reduction at week 13 in the 0.3-0.7 g/g subgroup; AMPLITUDE interim data are expected early 2027.
U.S. APOL1 opportunity estimate: 150,000 patients with proteinuria, two APOL1 alleles and no comorbidities, plus another 100,000 with comorbidities such as type 2 diabetes.
Development plans include physician and community education, genotyping initiatives and a potential companion diagnostic; autosomal dominant polycystic kidney disease is also under evaluation.
Latest events from Vertex Pharmaceuticals
- IgAN launch readiness and a packed 2027 kidney, pain and CAH catalyst calendar.VRTX
UBS Global Biopharma Conference 2026 - Revenue rose 12% as new franchises broadened growth; higher costs weighed on earnings.VRTX
Q3 2026 - Povetacicept cut IgAN proteinuria 52.0%; AMPLITUDE interim data target early 2027.VRTX
American Society of Nephrology (ASN) Kidney Week 2026 - Diversified pipeline, regulatory catalysts, and new assets drive growth beyond cystic fibrosis.VRTX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead.VRTX
Morgan Stanley 24th Annual Global Healthcare Conference - Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook.VRTX
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue up 12% to $3.33B; guidance raised; $10B Crinetics acquisition announced.VRTX
Q2 2026 - $10B acquisition adds leading endocrine assets, accelerating growth and portfolio diversification.VRTX
M&A announcement - Q3 revenue up 12% to $2.77–$2.8B; guidance raised as pipeline and launches drive growth.VRTX
Q3 2024 - 2024 revenue up 12% with new launches; Alpine charge led to GAAP loss, but 2025 outlook strong.VRTX
Q4 2024